Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,850
Closed -$213K 127
2023
Q2
$213K Buy
+1,850
New +$210K 0.24% 87
2023
Q1
Sell
-4,625
Closed -$513K 115
2022
Q4
$513K Buy
+4,625
New +$473K 0.73% 28
2018
Q3
$18K Hold
262
0.04% 357
2018
Q2
$15K Hold
262
0.04% 366
2018
Q1
$14K Sell
262
-157
-37% -$8.48K 0.04% 352
2017
Q4
$23K Sell
419
-1,121
-73% -$62.1K 0.05% 299
2017
Q3
$94K Sell
1,540
-2,980
-66% -$181K 0.17% 136
2017
Q2
$276K Buy
4,520
+42
+0.9% +$2.56K 0.44% 55
2017
Q1
$272K Buy
4,478
+3,146
+236% +$191K 0.39% 60
2016
Q4
$75K Buy
1,332
+351
+36% +$20.5K 0.12% 175
2016
Q3
$58K Sell
981
-222
-18% -$13K 0.1% 207
2016
Q2
$66K Sell
1,203
-602
-33% -$32K 0.11% 192
2016
Q1
$91K Sell
1,805
-898
-33% -$44K 0.14% 162
2015
Q4
$136K Buy
2,703
+910
+51% +$45.9K 0.19% 127
2015
Q3
$85K Sell
1,793
-6,199
-78% -$329K 0.12% 179
2015
Q2
$434K Buy
7,992
+4,373
+121% +$245K 0.5% 31
2015
Q1
$198K Buy
3,619
+1,551
+75% +$87.8K 0.24% 93
2014
Q4
$112K Sell
2,068
-552
-21% -$30.8K 0.13% 165
2014
Q3
$148K Buy
2,620
+490
+23% +$27.5K 0.19% 112
2014
Q2
$118K Buy
2,130
+3
+0.1% +$164 0.17% 145
2014
Q1
$115K Sell
2,127
-178
-8% -$9.22K 0.19% 141
2013
Q4
$110K Buy
+2,305
New +$105K 0.17% 141

Other funds holding MRK

Thompson Davis & Co's MRK Position: Q3 2023 in Review

Thompson Davis & Co sold out of Merck (MRK) in Q3 2023, closing a stake of 1,850 shares — an estimated $213K sold.

Thompson Davis & Co first reported a position in MRK in Q4 2013 and held it in 22 quarters. The position peaked at $513K in Q4 2022. 3,213 funds tracked by Wall St. Rank hold MRK as of Q3 2023.

  • Thompson Davis & Co reported no remaining Merck position as of Q3 2023 after selling out during the quarter.
  • Thompson Davis & Co sold 1,850 Merck shares in Q3 2023, an estimated $213K.
  • Thompson Davis & Co first reported a position in Merck in Q4 2013 and held it in 22 quarters.
  • Thompson Davis & Co's Merck position peaked at $513K in Q4 2022.
  • 3,213 funds tracked by Wall St. Rank held Merck as of Q3 2023.

Based on Thompson Davis & Co's 13F filing for Q3 2023, filed 9 Nov 2023.